{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:00Z","timestamp":1793730960472,"version":"4.6.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["771083"],"award-info":[{"award-number":["771083"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["279874820"],"award-info":[{"award-number":["279874820"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["403224013"],"award-info":[{"award-number":["403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["440603844"],"award-info":[{"award-number":["440603844"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["461704932"],"award-info":[{"award-number":["461704932"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["2520DAT111"],"award-info":[{"award-number":["2520DAT111"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["493659010"],"award-info":[{"award-number":["493659010"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.esmoop.2024.103706","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T21:48:47Z","timestamp":1727992127000},"page":"103706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets"],"prefix":"10.1016","volume":"9","author":[{"given":"L.","family":"Kehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"J\u00f6rdens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Loosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103706_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Global Burden of Disease Cancer Collaboration","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2024.103706_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.esmoop.2024.103706_bib5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103706_bib6","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1055\/a-2189-8567","article-title":"S3-Leitlinie \u201cDiagnostik und Therapie bili\u00e4rer Karzinome\u201d \u2013 Langversion 4.0","volume":"62","author":"Gro\u00df","year":"2024","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.esmoop.2024.103706_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib8","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1245\/s10434-019-07353-4","article-title":"Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma","volume":"26","author":"Hu","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00268-007-9001-y","article-title":"Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications","volume":"31","author":"Hasegawa","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.esmoop.2024.103706_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103706_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.esmoop.2024.103706_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103706_bib15","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2217\/fon-2021-1302","article-title":"Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety","volume":"18","author":"Khankhel","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib17","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12885-023-10972-6","article-title":"Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine\/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)","volume":"23","author":"Kehmann","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib20","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103706_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib23","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2024.103706_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what\u2019s now and what\u2019s next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","article-title":"Precision medicine in cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2024.103706_bib27","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820983013","article-title":"Targeting BRAF-mutant biliary tract cancer: recent advances and future challenges","volume":"27","author":"Rizzo","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.esmoop.2024.103706_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.humpath.2013.11.001","article-title":"Molecular characterization of gallbladder cancer using somatic mutation profiling","volume":"45","author":"Javle","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib32","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib34","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/cells11233929","article-title":"FGFR inhibitors in cholangiocarcinoma-a novel yet primary approach: where do we stand now and where to head next in targeting this axis?","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.esmoop.2024.103706_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103706_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib40","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2024.103706_bib41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2024.103706_bib42","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/cancers13133222","article-title":"Next-generation biomarkers for cholangiocarcinoma","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103706_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5582\/bst.2020.03240","article-title":"Systemic treatment of advanced or recurrent biliary tract cancer","volume":"14","author":"Zhang","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.esmoop.2024.103706_bib44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib45","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/hep.27659","article-title":"Determining the fate of hepatic cells by lineage tracing: facts and pitfalls","volume":"61","author":"Lemaigre","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2024.103706_bib46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib47","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2024.103706_bib49","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103706_bib50","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib51","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2024.103706_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11523-022-00933-7","article-title":"Clinical outcomes after progression on first-line therapies in IDH1 mutated versus wild-type intrahepatic cholangiocarcinoma patients","volume":"18","author":"Rimini","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib54","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2024.103706_bib55","article-title":"IDH inhibitors in advanced cholangiocarcinoma: another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.esmoop.2024.103706_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108170","article-title":"Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions","volume":"237","author":"Lavacchi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2024.103706_bib57","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1002\/sim.6923","article-title":"Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method","volume":"35","author":"Zhang","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2024.103706_bib58","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib59","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-019-00684-6","article-title":"Novel IDH1-targeted glioma therapies","volume":"33","author":"Karpel-Massler","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.esmoop.2024.103706_bib60","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib61","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.103706_bib62","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.esmoop.2024.103706_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103706_bib66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/genes13020271","article-title":"Molecularly guided drug repurposing for cholangiocarcinoma: an integrative bioinformatic approach","volume":"13","author":"Venkatraman","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.esmoop.2024.103706_bib67","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.3390\/cancers14133284","article-title":"Novel drug candidate prediction for intrahepatic cholangiocarcinoma via hub gene network analysis and connectivity mapping","volume":"14","author":"Xiao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103706_bib68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00292-021-01022-8","article-title":"Detection of BRAF V600E mutation in metastatic colorectal carcinoma : a QuIP round robin test","volume":"43","author":"J\u00f6hrens","year":"2022","journal-title":"Pathologe"},{"key":"10.1016\/j.esmoop.2024.103706_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-004-1046-9","article-title":"Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and P53 mutations and microsatellite instability","volume":"445","author":"Saetta","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/j.esmoop.2024.103706_bib70","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib71","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.3800204","article-title":"The V599E BRAF mutation is uncommon in biliary tract cancers","volume":"17","author":"Goldenberg","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103706_bib73","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmoop.2024.103706_bib74","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions","volume":"44","author":"Voss","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib75","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.21037\/jgo.2017.01.06","article-title":"Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion","volume":"8","author":"Kocsis","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib76","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103706_bib77","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib78","doi-asserted-by":"crossref","first-page":"E98","DOI":"10.21037\/jgo.2016.09.13","article-title":"Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review","volume":"7","author":"Lavingia","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib79","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21037\/jgo.2019.03.05","article-title":"Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV","volume":"10","author":"Bunyatov","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib80","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib81","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103706_bib82","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib83","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8278(01)00106-4","article-title":"Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma","volume":"35","author":"Momoi","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.esmoop.2024.103706_bib85","first-page":"604","article-title":"Analysis of microsatellite instability, K-ras gene mutation and P53 protein overexpression in intrahepatic cholangiocarcinoma","volume":"49","author":"Isa","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.esmoop.2024.103706_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-018-0341-y","article-title":"Microsatellite instability in prostate cancer by PCR or next-generation sequencing","volume":"6","author":"Hempelmann","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib87","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","article-title":"Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma","volume":"13","author":"Arulananda","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib88","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmoop.2024.103706_bib89","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib91","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.esmoop.2024.103706_bib92","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (Pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients With HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib95","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4008","article-title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)","volume":"41","author":"Pant","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.esmoop.2024.103706_bib97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/187152708783885174","article-title":"The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors","volume":"7","author":"Skaper","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.esmoop.2024.103706_bib98","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib99","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","article-title":"NTRK insights: best practices for pathologists","volume":"35","author":"Hechtman","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2024.103706_bib100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib101","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103706_bib102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boil\u00e8ve","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmoop.2024.103706_bib103","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2023-0963","article-title":"Brightline-2: a phase IIa\/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors","volume":"20","author":"Yoo","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib104","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and Nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib106","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib107","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.esmoop.2024.103706_bib108","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2021.08.2082","article-title":"LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group","volume":"32","author":"Perkhofer","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib109","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103706_bib110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A\u00a0randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103706_bib111","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:13:25Z","timestamp":1729815205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2059702924014765"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103706","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103706"}}